Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Open Label Phase II Study of Weekly Gemcitabine Plus Pazopanib Versus Weekly Gemcitabine Alone in the Treatment of Patients With Persistent or Relapsed Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma

NCT01610206 is registered in ClinicalTrials.gov with Linda R Duska as lead sponsor.

NCT NCT01610206
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01610206 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Open Label Phase II Study of Weekly Gemcitabine Plus Pazopanib Versus Weekly Gemcitabine Alone in the Treatment of Patients With Persistent or Relapsed Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma
Lead sponsor
Linda R Duska
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2012
Completion date
December 31, 2020
Enrollment
148 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

fallopian tube cancer, ovarian cancer, peritoneal cancer